Antigen Express is a platform technology and product-based
company developing proprietary vaccine formulations for large,
unmet medical needs. Our focus is on stimulating critical
members of the immune response, known as CD4+ T helper cells.
The technology allows for antigen-specific stimulation or
suppression of a T-helper response to virtually any antigen of
known pathogenic potential. Using this technology, Antigen
Express is building a deep pipeline of therapeutics aimed at a
variety of major diseases, including cancer, infectious diseases
and autoimmune-based syndromes.
Antigen Express immunotherapies are based on highly selective
modulation of the immune response through potent and
antigen-specific stimulation of CD4+ T helper cells, resulting
in highly effective agents with very low toxicity as compared
with traditional cancer chemotherapy. Advances in
immunology, in particular those made by the founder of Antigen
Express, Dr. Robert Humphreys, have demonstrated that it is
possible to enlist the help of the immune system in combating
diseases, including cancer. The specificity inherent in a
targeted immune response is unparalleled by traditionally
designed small molecules. The therapies developed at
Antigen Express intervene at the critical stage of antigen
presentation to modulate the immune response. This targeted
approach results in a potent up or down regulation of vital
members of the immune system.
The technologies developed at Antigen Express are novel and
highly complementary to existing approaches of immune
modification. They have the added advantage of being
‘off-the-shelf’ products produced by entirely synthetic means.
Therefore, the company is uniquely positioned to both develop
specific products as well as enter into partnerships where
Antigen Express technology enhances the corporate partners’
strategic goals or product portfolio.
» return to top